Assuming report is required, the following results were found.

  • Global Multiple Sclerosis Market by Types, Applications, Countries, Companies and Forecasts to 2024 covered in a Latest Research - Market Research Reporting

    Biogen, Genzyme (Sanofi), GlaxoSmithKline, Merck Serono, Novartis, Pfizer, Teva and others which are profiled in this report as well in terms of Sales, Price, Revenue, Gross Margin and Market Share (2017-2018). Access Report Details at:...

    https://mschristian.org/index.php/blog/global-multiple-sclerosis-market-by-types-applications-countries-companies-and-forecasts-to-2024-covered-in-a-latest-research-market-research-reporting
  • Global Multiple Sclerosis Drugs Production Market Share, Revenue, and Average Price by Manufacturers Shared in a Latest Research Report - Market Research Writeup

    resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Access Report Details at: https://www.themarketreports.com/report/global-multiple-sclerosis-drugs-market-research-report The global Multiple...

    https://mschristian.org/index.php/blog/global-multiple-sclerosis-drugs-production-market-share-revenue-and-average-price-by-manufacturers-shared-in-a-latest-research-report-market-research-writeup
  • Blue Cross Blue Shield Association Reports Americans with Multiple Sclerosis are Three Times More Likely to Have Behavioral Health Conditions - BioSpace

    and substance use disorder, than the overall population, according to a new Blue Cross Blue Shield Association (BCBSA) report. The Health Impact of Multiple Sclerosis, part of the Blue Cross Blue Shield, The Health of America Report® series, also found...

    https://mschristian.org/index.php/blog/blue-cross-blue-shield-association-reports-americans-with-multiple-sclerosis-are-three-times-more-likely-to-have-behavioral-health-conditions-biospace
  • Humira, Rituxan top list of U.S. drugs with biggest price increases: report - Physician's Weekly

    list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by...

    https://mschristian.org/index.php/blog/humira-rituxan-top-list-of-u-s-drugs-with-biggest-price-increases-report-physician-s-weekly
  • Watchdog group cites 7 best-selling drugs it says didn’t warrant price increases - The Boston Globe

    two years, from $99 to $109 for a single 240-milligram pill, raising health care costs by $313 million, according to a report Tuesday by the Institute for Clinical and Economic Review. The drug ranked seventh among the seven drugs with the biggest...

    https://mschristian.org/index.php/blog/watchdog-group-cites-7-best-selling-drugs-it-says-didn-t-warrant-price-increases-the-boston-globe
  • NetNoggin® releases exploratory analysis "Healthcare Provider Needs in the NASH Market" - P&T Community

    This exploratory analysis was inspired by NetNoggin's involvement in the NAFLD community after publishing their syndicated report, NetNog: #genesis® NASH (including NAFL). With this report, NetNoggin® has helped pharmaceutical companies change secondary...

    https://mschristian.org/index.php/blog/netnoggin-releases-exploratory-analysis-healthcare-provider-needs-in-the-nash-market-p-t-community
  • Top 9 Drugs With the Biggest Price Increases Over 2 Years - Pharmacy Times

    surges over the past 2 years, adding $5.1 billion to overall drug spending during this time period, according to a new report. Furthermore, 7 of these 9 drugs were found by the Institute of Clinical and Economic Review (ICER) to be lacking sufficient...

    https://mschristian.org/index.php/blog/top-9-drugs-with-the-biggest-price-increases-over-2-years-pharmacy-times
  • Why Is Celgene (CELG) Up 6.1% Since Last Earnings Report? - Yahoo Finance

    Is Celgene (CELG) Up 6.1% Since Last Earnings Report? Yahoo Finance It has been about a month since the last earnings report for Celgene (CELG). Shares have added about 6.1% in that time frame, outperforming the S&P 500. Original link Why Is Celgene...

    https://mschristian.org/index.php/blog/why-is-celgene-celg-up-6-1-since-last-earnings-report-yahoo-finance
  • Electronic Drug Delivery Systems Market Size Reach US$ 12.1 Billion by 2026 - Yahoo Finance

    (GLOBE NEWSWIRE) -- Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Electronic Drug Delivery Systems Market By Product (Electronic Wearable Infusion Pumps, Electronic Injection Pens,...

    https://mschristian.org/index.php/blog/electronic-drug-delivery-systems-market-size-reach-us-12-1-billion-by-2026-yahoo-finance
  • Biogen Strengthens MS & SMA Portfolio as Competition Lurks - Yahoo Finance

    from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Alkermes plc (ALKS) : Free...

    https://mschristian.org/index.php/blog/biogen-strengthens-ms-sma-portfolio-as-competition-lurks-yahoo-finance
  • Aubagio (teriflunomide)

    syndrome, which is a medical emergency. It causes painful sores on your mouth, throat, eyes, or genitals. It was reported that one person who took Aubagio developed toxic epidermal necrolysis (TEN), which was fatal. TEN is Stevens-Johnson syndrome that...

    https://mschristian.org/index.php/blog/aubagio-teriflunomide
  • New app offers faster and easier assessment for multiple sclerosis

    Johns Hopkins Medicine researchers report they have developed and validated a tablet-based app that offers a faster, easier and more accurate way for health care providers who don't have specialized training to assess the cognitive function of people...

    https://mschristian.org/index.php/blog/new-app-offers-faster-and-easier-assessment-for-multiple-sclerosis
  • International MS Genetics Consortium Confirms 233 MS-Related Gene Variations in Largest Study to Date

    to ways to prevent it.The IMSGC, a worldwide group of investigators collaborating to understand the genetic basis of MS, report this study in the magazine Science (365, eaav7188 [2019]). “This study greatly expands our knowledge of the genetic...

    https://mschristian.org/index.php/blog/international-ms-genetics-consortium-confirms-233-ms-related-gene-variations-in-largest-study-to-date
  • Tecfidera (dimethyl fumarate)

    a side effect that has occurred in studies of Tecfidera. However, some people who take Tecfidera have had hair loss. In one report, a woman who started taking Tecfidera began to lose hair after taking the drug for two to three months. Her hair loss...

    https://mschristian.org/index.php/blog/tecfidera-dimethyl-fumarate
  • Chemical compound produces beneficial inflammation, remyelination that could help treat multiple sclerosis

    for the proper functioning of the brain and spinal cord. Researchers at the University of California, Riverside, now report that indazole chloride, a synthetic compound that acts on one form of the body's estrogen receptors previously shown to reduce...

    https://mschristian.org/index.php/blog/chemical-compound-produces-beneficial-inflammation-remyelination-that-could-help-treat-multiple-sclerosis
  • #ECTRIMS2019 - Transplanting MSCs Safe, Helps Stop Progressive MS - Multiple Sclerosis News Today

    effects in progressive multiple sclerosis following autologous mesenchymal stem cells (MSC) transplantation: report of a randomised phase IIb double blind trial.“ Recent studies have raised hope for adult stem cell therapy as an MS treatment to slow...

    https://mschristian.org/index.php/blog/ectrims2019-transplanting-mscs-safe-helps-stop-progressive-ms-multiple-sclerosis-news-today
  • Economic Factors Amplify Burden of Disease for Patients With Multiple Sclerosis

    study involving 16,808 people with MS from 16 countries (mean age was 51.5 years, 52% had relapsing MS). Participants reported on their disease, its impact on health-related quality of life, and consumption of healthcare resources. The goal of the...

    https://mschristian.org/index.php/blog/economic-factors-amplify-burden-of-disease-for-patients-with-multiple-sclerosis
  • Studies Report on Efforts to Optimize Rituximab in MS, NMOSD - The Center for Biosimilars

    While rituximab does not carry indications for the treatment of multiple sclerosis (MS) or aquaporin-4-positive (AQP4) neuromyelitis optica spectrum disorder (NMOSD), the CD20-depleting therapy and its biosimilars are commonly used off-label, as the...

    https://mschristian.org/index.php/blog/studies-report-on-efforts-to-optimize-rituximab-in-ms-nmosd-the-center-for-biosimilars
  • Short-Duration Opioid Protocol Feasible for Tonsillectomy

    average, the patients received almost twice as many opioid tablets for post-tonsillectomy pain relief as otolaryngologists reported in a recent survey, and almost 40% of the patients received refills within 30 days of surgery. Despite involving a...

    https://mschristian.org/index.php/blog/short-duration-opioid-protocol-feasible-for-tonsillectomy
  • New Study Shows Why Myelin Repair May Fall Short in MS

    Inflammation Can Hijack Brain Repair Cells to Ramp Up Immune Attacks in MS, Researchers Report 09.04.19 Society-funded researchers discover that immature brain cells can be hijacked to act as immune helpers that can ramp up MS-related damage to myelin...

    https://mschristian.org/index.php/blog/new-study-shows-why-myelin-repair-may-fall-short-in-ms

Results 1 - 20 of 46
 
 

Follow Us on Twitter

Follow Us On Twitter - Image